Analyst consensus rating
NeuroOne Medical Technologies Analyst Rating: Strong Buy
NMTC is rated Strong Buy by 3 analysts with a $7.27 target. As of 2026-08-20.
Direct answer
NeuroOne Medical Technologies's consensus rating is Strong Buy.
3 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $7.27.
Forecast evidence checked August 20, 2026.
Get free NeuroOne Medical Technologies email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $2.15
- Average price target
- $7.27
- High price target
- $8.80
- Low price target
- $5.00
- Low target gap
- +132.6%
- Target upside
- +238%
- High target gap
- +309.3%
- Target range width
- 176.7%
- Consensus rating
- Strong Buy
- Analysts
- 3
- Evidence date
- August 20, 2026
- Valid through
- August 27, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for NeuroOne Medical Technologies?
NeuroOne Medical Technologies has a verified Strong Buy consensus. The same dataset has an average price target of $7.27.
How far are NeuroOne Medical Technologies's low and high targets from the recorded price?
The low target implies +132.6%, while the high target implies +309.3%.
How many analysts are included in NeuroOne Medical Technologies's consensus?
The verified consensus includes 3 analysts.
How is NeuroOne Medical Technologies's target upside or downside calculated?
The average target of $7.27 is divided by the recorded price of $2.15, then one is subtracted to produce +238%. This does not guarantee a future return.
When was NeuroOne Medical Technologies's analyst forecast verified?
The data was verified on 2026-08-20. The dataset is valid through 2026-08-27.